David Stejskal | Nanobiotechnology | Best Researcher Award

Prof. Dr. David Stejskal | Nanobiotechnology | Best Researcher Award

Professor, MD, PhD, MBA, EuSpLM, Head of the Institute of Laboratory Medicine | University Hospital in Ostrava | Czech Republic

Prof. Dr. David Stejskal, MD, PhD, MBA, EuSpLM, is a distinguished researcher and academic leader in the field of laboratory medicine, clinical biochemistry, and internal medicine. His research primarily focuses on the identification and clinical validation of novel biomarkers relevant to metabolic, cardiovascular, nephrological, and inflammatory diseases. With over 3,767 citations, an h-index of 29 (Scopus), and more than 200 peer-reviewed publications, his scholarly influence spans translational diagnostics and clinical applications in metabolic and endocrine disorders. His most cited works include pioneering studies on fatty acid binding proteins (FABP), chemerin, and FGF23, which have significantly advanced understanding of biomarkers in metabolic syndrome, chronic kidney disease, and cardiovascular risk assessment. Prof. Dr. David Stejskal’s research group has also contributed substantially to the development of novel diagnostic markers for diabetes, obesity, and atherosclerosis, as well as the evaluation of inflammatory and oxidative stress parameters in internal medicine. Beyond journal publications, he has authored and co-authored several scientific books such as Metabolic Diseases of Mass Incidence, Dyslipidemia, and Urolithiasis, alongside chapters in specialized medical encyclopedias. His work has been instrumental in shaping biomarker-based diagnostic strategies across Central Europe. Prof. Dr. David Stejskal has received notable research and organizational recognitions, including the OMICS Award (USA) for excellence in translational medicine and the Czech Society of Clinical Biochemistry Award. As an editorial contributor, reviewer, and conference organizer, he has significantly influenced international collaboration in laboratory and clinical research. His continued focus on biochemical innovation, diagnostic optimization, and translational research highlights his contribution to advancing laboratory medicine and evidence-based clinical diagnostics globally.

Profiles: Scopus | ORCID | ResearchGate | Sci Profiles | Web of Science

Featured Publications

1. Sigutova, R., Evin, L., Kusnierova, P., Svagera, Z., Branny, M., & Vaclavik, J. (2025). Specific microRNAs for heart failure: Reference values in whole blood. Biomedicines, 13(10), 2559. https://doi.org/10.3390/biomedicines13102559

2. Urinovska, R., Sistik, P., Buzga, M., & Stejskal, D. (2024). Fast and easy simultaneous determination of riboflavin, folic acid, all-trans-retinol and α-tocopherol in human serum by LC/MS/MS for bariatric patients. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmae035

3. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2024). Integration of a bead-based immunoassay on a commercial PCR-performing POC device. Proceedings, 2024(097166). https://doi.org/10.3390/proceedings2024097166

4. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2023). Patient stratification for antibiotic prescriptions based on the bound-free phase detection immunoassay of C-reactive protein in serum samples. Biosensors, 13(12), 1009. https://doi.org/10.3390/bios13121009

5. Plášek, J., Lazárová, M., Dodulík, J., Švagera, Z., Všianský, F., & Václavík, J. (2022). Secretoneurin as a novel biomarker of cardiovascular episodes: Are we there yet? A narrative review. Journal of Clinical Medicine, 11(23), 7191. https://doi.org/10.3390/jcm11237191

Sunny Kumar | Nanobiotechnology | Young Scientist Award

Mr. Sunny Kumar | Nanobiotechnology | Young Scientist Award

Researcher, CSIR-Indian Institute Of Chemical Biology, India

Mr. Sunny Kumar is an emerging researcher in cancer biology and nanomedicine, recognized for his interdisciplinary contributions that bridge molecular oncology, tumor microenvironment studies, and nanotechnology-driven therapeutics. With an h-index of 6, 11 publications, and 148 citations (as indexed in Scopus), his research reflects both productivity and impact within translational cancer science. His primary research focuses on elucidating the molecular mechanisms underlying glioma, colorectal, and breast cancer progression, emphasizing protein quality control systems such as the ubiquitin-proteasome system and their regulatory influence on oncogenic signaling. Mr. Sunny Kumar has explored novel therapeutic targets like E3 ligases (CHIP), PD-1/PD-L1 pathways, and HAUSP-MDM2 axes, offering valuable insights for cancer immunotherapy and personalized treatment strategies. In addition to mechanistic studies, Mr. Sunny Kumar integrates nanobiotechnology and drug delivery innovation, developing nanoparticle-based formulations capable of crossing the blood–brain barrier for targeted glioma therapy. His research on dual-drug nanotherapeutics and carbon nanotube-based diagnostic platforms has contributed to the advancement of precision medicine approaches for difficult-to-treat cancers. He has published extensively as first or corresponding author in high-impact journals such as Genes & Diseases (IF 9.4), BBA-Molecular Cell Research (IF 3.7), International Journal of Pharmaceutics (IF 5.2), and Journal of Medicinal Chemistry (IF 6.8). His scholarly output also includes multiple book chapters with Springer and Taylor & Francis, covering cancer proteomics, personalized therapy, and nanotherapeutics. Mr. Sunny Kumar serves as a peer reviewer for reputed journals, including BBA–Reviews on Cancer and Experimental Cell Research, further demonstrating his engagement in the scientific community. His research exhibits a robust methodological framework, integrating cell and molecular biology, bioinformatics, animal models, and nanocarrier engineering. Collectively, Mr. Sunny Kumar’s scientific endeavors underscore a commitment to next-generation cancer therapeutics, aiming to translate molecular discoveries into clinically viable nanomedicine solutions for precision oncology.

Profile: Scopus | ORCID | Google Scholar | RsearchGate

Featured Publications

1. Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2023). Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases, 10(4), 1318–1350.

2. Kumar, S., Basu, M., & Ghosh, M. K. (2022). Chaperone-assisted E3 ligase CHIP: A double agent in cancer. Genes & Diseases, 9(6), 1521–1555.

3. Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2023). COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology, 89(1), 114–149.

4. Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023). COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4), 1402–1428.

5. Ghosh, M. K., Kumar, S., Ganguly, K. K., Ghosh, P., Tabassum, S., Basu, B., & Basu, M. (2023). COVID-19 and cancer: Insights into their association and influence on genetic and epigenetic landscape. Epigenomics, 15(4), 227–248.